Qarziba Market Report 2026

Qarziba Market Overview

• The Qarziba market growth in the historic period has been driven by increasing incidence of high-risk neuroblastoma, advancements in monoclonal antibody development • Market expansion is supported by expansion of precision oncology research, rising adoption of GD2-targeted therapies • Growth Driver: Impact Of Growing Cancer Prevalence On The Expansion Of The Market • Market Trend: Farma Mondo–recordati Agreement Advances Qarziba Availability In Hong Kong • North America was the largest region in 2025.

What Is Covered Under Qarziba Market?

Qarziba (dinutuximab beta) is a monoclonal antibody used to treat high-risk neuroblastoma in pediatric patients. It targets GD2, a molecule found in neuroblastoma cells, helping the immune system destroy these cancerous cells. It is typically used in a comprehensive treatment regimen, including immunotherapy. Qarziba improves survival rates and reduces the risk of relapse in neuroblastoma patients. The main indication types of qarziba are high-risk neuroblastoma and relapsed or refractory neuroblastoma. High-risk neuroblastoma refers to an aggressive type of cancer in children, characterized by abnormal growth of nerve cells in the adrenal glands, neck, chest, abdomen, or pelvis, often diagnosed at advanced stages. The distribution channels are hospital pharmacies, retail pharmacies, and online pharmacies, and it is used by various end users such as hospitals and specialized oncology clinics.

What Is The Qarziba Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of precision oncology research, rising adoption of GD2-targeted therapies, increasing investments in pediatric cancer immunotherapy, growing focus on personalized treatment protocols, expansion of global access to advanced oncology drugs. Major trends in the forecast period include expansion of targeted immunotherapy adoption, growing use of monoclonal antibodies in pediatric oncology, increasing focus on relapse prevention therapies, rising integration of immunotherapy in multimodal treatment regimens, enhanced clinical monitoring of treatment outcomes.

Global Qarziba Market Segmentation

1) By Indication: High-Risk Neuroblastoma, Relapsed Or Refractory Neuroblastoma 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Hospitals, Specialized Oncology Clinics

What Is The Driver Of The Qarziba Market?

The increasing prevalence of cancer will propel the growth of the qarziba market going forward. The rising prevalence of cancer can be attributed to several factors, including an aging population, lifestyle changes such as smoking, poor diet, lack of physical activity, and genetic predispositions. Qarziba (dinutuximab beta) is used in pediatric oncology to treat high-risk neuroblastoma by targeting GD2-expressing cancer cells, enhancing immune-mediated destruction, and reducing relapse risk in this aggressive form of cancer. For instance, in August 2024, according to a report published by the Australian Institute of Health and Welfare, an Australian-based national agency for information and statistics on Australia's health and welfare, by 2034, Australia is projected to have approximately 209,000 new cancer diagnoses, a significant increase from the estimated 169,000 cases expected in 2024, reflecting the impact of a growing population and rising cancer rates. Therefore, the increasing prevalence of cancer is expected to drive the qarziba industry.

Key Players In The Global Qarziba Market

Major companies operating in the qarziba market are EUSA Pharma (UK) Ltd

Global Qarziba Market Trends and Insights

Major companies operating in the Qarziba market are adopting a strategic partnership approach to enhance technology integration and expand market reach. A strategic partnership typically refers to a collaborative relationship between two or more organizations where they combine their resources, expertise, and efforts to achieve common goals or objectives. For instance, in July 2024, Farma Mondo Hong Kong Ltd., a Hong Kong-based subsidiary of the Switzerland-based Farma Mondo Group specializing in market access and specialty pharmaceutical distribution, announced an exclusive license and distribution agreement with Recordati UK Ltd. for Qarziba (dinutuximab beta) in Hong Kong. Under this arrangement, Farma Mondo Hong Kong assumes the role of local marketing authorization holder and will oversee the commercial distribution of the neuroblastoma treatment within the market. Recordati UK Ltd. is a UK-based pharmaceutical company.

What Are Latest Mergers And Acquisitions In The Qarziba Market?

In July 2024, Farma Mondo Hong Kong Ltd, a China-based pharmaceutical company, partnered with Recordati UK Ltd. to distribute Qarziba in Hong Kong. With this partnership, Farma Mondo will serve as the local Marketing Authorization Holder (MAH), overseeing the commercial distribution of Qarziba, a treatment for high-risk neuroblastoma primarily affecting children under five. Recordati UK Ltd is a UK-based pharmaceutical company.

Regional Insights

North America was the largest region in the qarziba market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Qarziba Market?

The qarziba market consists of sales of monoclonal antibody therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Qarziba Market Report 2026?

The qarziba market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the qarziba industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.